IP Library Patent Application 12572473
Patent Application
App. No. 12/572,473

METHOD FOR IDENTIFYING MALIGNANCIES IN BARRETT'S ESOPHAGUS USING WHITE LIGHT ENDOSCOPY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/572,473
Abstract

A method is described for computing a statistically significant difference between dysplasia and Barrett's esophagus (both with and without inflammatory component) using a discriminate function with diffuse reflectance measurements performed at a minimum of four different wavelengths of 485, 513, 598, and 629 nm. The discriminate function found depends both on local blood fraction volume T HB and oxygenation SO 2 . A pull-back approach of spectral data acquisition is disclosed which takes into account tissue motility in esophagus and measurement geometry peculiarities. The pull-back approach provides a significant improvement of measurement reproducibility and reduction of data deviation by 75-100%, resulting in a better discrimination between different histological groups.

Claims (13)

1 . A method for assessing cancer risk by diffuse reflectance spectroscopy, comprising the steps of:

illuminating tissue with light in a wavelength range that includes at least a portion of the visible spectrum,

selecting at least four distinct narrow wavelength bands in the wavelength range of the illumination light,

measuring intensity of diffusely reflected light in the at least four distinct narrow wavelength bands at different tissue sampling sites,

computing a parameter value with a predetermined linear discriminate function, and

assessing malignancy of the tissue based on the computed parameter values from the different tissue sampling sites.

2 . The method of claim 1 , wherein the at least four distinct narrow wavelength bands include the wavelength 485±5, 513±5, 598±2, 629±5 nm.

3 . The method of claim 2 , wherein the discriminate function is

B 4=−14.32+626.88* Rd 485 −721.31* Rd 513 +253.76* Rd 598 +75.16* Rd 629

and the computed parameter value is represented by B4.

4 . The method of claim 3 , wherein the diffuse reflectance measured at 485±5, 513±5, 598±2, 629±5 nm is normalized with respect to reflectance in the infrared wavelength range (650-750 nm) where absorption of blood is negligible.

5 . The method of claim 1 , further comprising the steps of lifting a measurement probe (pull-back) from close proximity to the tissue surface to a distance where the measurement probe no longer shadows the tissue.

6 . The method of claim 6 , wherein the lifting is repeated at least once for a tissue spot.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 8, 2017
From: MIDCAP FUNDING IV TRUST (AS SUCCESSOR AGENT TO MIDCAP FINANCIAL TRUST)
To: NOVADAQ TECHNOLOGIES INC.; NOVADAQ CORP.
Reel/Frame 043786/0344 →
RELEASE OF SECURITY INTEREST Recorded Sep 8, 2017
From: MIDCAP FINANCIAL TRUST
To: NOVADAQ TECHNOLOGIES INC.; NOVADAQ CORP.
Reel/Frame 043788/0799 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2014
From: DOUPLIK, ALEXANDRE; ADLER, DESMOND C; WILSON, BRIAN; MARCON, NORMAN
To: NOVADAQ TECHNOLOGIES INC.
Reel/Frame 034380/0633 →